[HTML][HTML] Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
L Zhong, Y Li, L Xiong, W Wang, M Wu… - Signal transduction and …, 2021 - nature.com
Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
The RAS oncogene is both the most frequently mutated oncogene in human cancer and the
first confirmed human oncogene to be discovered in 1982. After decades of research, in …
first confirmed human oncogene to be discovered in 1982. After decades of research, in …
Alignment of spatial genomics data using deep Gaussian processes
Spatially resolved genomic technologies have allowed us to study the physical organization
of cells and tissues, and promise an understanding of local interactions between cells …
of cells and tissues, and promise an understanding of local interactions between cells …
KRAS: From undruggable to a druggable Cancer Target
D Uprety, AA Adjei - Cancer treatment reviews, 2020 - Elsevier
RAS is the most frequently mutated oncogene in human cancers, with mutations in about
30% of all cancers. RAS exists in three different isoforms (K-RAS, H-RAS and N-RAS) with …
30% of all cancers. RAS exists in three different isoforms (K-RAS, H-RAS and N-RAS) with …
[HTML][HTML] Targeting the untargetable KRAS in cancer therapy
P Liu, Y Wang, X Li - Acta Pharmaceutica Sinica B, 2019 - Elsevier
RAS is one of the most well-known proto-oncogenes. Its gain-of-function mutations occur in
approximately 30% of all human cancers. As the most frequently mutated RAS isoform …
approximately 30% of all human cancers. As the most frequently mutated RAS isoform …
[HTML][HTML] The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and …
C Liu, S Zheng, R Jin, X Wang, F Wang, R Zang, H Xu… - Cancer letters, 2020 - Elsevier
Immune checkpoint inhibitors against PD-1/PD-L1 yield improved survival rates of KRAS-
mutant NSCLC patients, who conferred a poor prognosis without effective targeted therapy …
mutant NSCLC patients, who conferred a poor prognosis without effective targeted therapy …
[HTML][HTML] The current understanding on the impact of KRAS on colorectal cancer
M Meng, K Zhong, T Jiang, Z Liu, HY Kwan… - Biomedicine & …, 2021 - Elsevier
KRAS (kirsten rat sarcoma viral oncogene) is a member of the RAS family. KRAS mutations
are one of most dominant mutations in colorectal cancer (CRC). The impact of KRAS …
are one of most dominant mutations in colorectal cancer (CRC). The impact of KRAS …
CA 19-9: biochemical and clinical aspects
Abstract CA19-9 (carbohydrate antigen 19-9, also called cancer antigen 19-9 or sialylated
Lewis a antigen) is the most commonly used and best validated serum tumor marker for …
Lewis a antigen) is the most commonly used and best validated serum tumor marker for …
Diagnosis and molecular classification of lung cancer
J Rodriguez-Canales, E Parra-Cuentas… - Lung Cancer: Treatment …, 2016 - Springer
Lung cancer is a complex disease composed of diverse histological and molecular types
with clinical relevance. The advent of large-scale molecular profiling has been helpful to …
with clinical relevance. The advent of large-scale molecular profiling has been helpful to …
Efficacy of immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer (NSCLC)
A Jeanson, P Tomasini, M Souquet-Bressand… - Journal of Thoracic …, 2019 - Elsevier
Introduction KRAS mutation is the most frequent molecular alteration found in advanced
NSCLC; it is associated with a poor prognosis without available targeted therapy. Treatment …
NSCLC; it is associated with a poor prognosis without available targeted therapy. Treatment …